Table 2.
Summary of subjects with measurable antibodies prior to completion of second dose
| Moderna | Pfizer | Combined | |
|---|---|---|---|
| Individuals With Data Collected Prior to 2nd Dose | 26 | 10 | 36 |
| Antibody Produced Before 2nd Dose | 23 (88%) | 5 (50%) | 28 (77%) |
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.